The impact of cancer on the risk of death with a functioning graft of Italian kidney transplant recipients.
cancer
epidemiology
kidney transplantation
malignancy
neoplasia
nephrology
science
translational research
Journal
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
ISSN: 1600-6143
Titre abrégé: Am J Transplant
Pays: United States
ID NLM: 100968638
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
04
08
2021
received:
20
05
2021
accepted:
26
08
2021
pubmed:
1
9
2021
medline:
7
4
2022
entrez:
31
8
2021
Statut:
ppublish
Résumé
This study assessed the impact of cancer on the risk of death with a functioning graft of kidney transplant (KT) recipients, as compared to corresponding recipients without cancer. A matched cohort study was conducted using data from a cohort of 13 245 individuals who had undergone KT in 17 Italian centers (1997-2017). Cases were defined as subjects diagnosed with any cancer after KT. For each case, two controls matched by gender, age, and year at KT were randomly selected from cohort members who were cancer-free at the time of diagnosis of the index case. Overall, 292 (20.5%) deaths with a functioning graft were recorded among 1425 cases and 238 (8.4%) among 2850 controls. KT recipients with cancer had a greater risk of death with a functioning graft (hazard ratio, HR = 3.31) than their respective controls. This pattern was consistent over a broad range of cancer types, including non-Hodgkin lymphoma (HR = 33.09), lung (HR = 20.51), breast (HR = 8.80), colon-rectum (HR = 3.51), and kidney (HR = 2.38). The survival gap was observed throughout the entire follow-up period, though the effect was more marked within 1 year from cancer diagnosis. These results call for close posttransplant surveillance to detect cancers at earlier stages when treatments are more effective in improving survival.
Identifiants
pubmed: 34464503
doi: 10.1111/ajt.16825
pii: S1600-6135(22)08101-1
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
588-598Informations de copyright
© 2021 The American Society of Transplantation and the American Society of Transplant Surgeons.
Références
Rana A, Gruessner A, Agopian VG, et al. Survival benefit of solid-organ transplant in the United States. JAMA Surg. 2015;150(3):252-259.
El-Agroudy AE, Bakr MA, Shehab El-Dein AB, et al. Death with functioning graft in living donor kidney transplantation: analysis of risk factors. AJN. 2003;23(3):186-193.
Ojo AO, Hanson JA, Wolfe RA, et al. Long-term survival in renal transplant recipients with graft function. Kidney Int. 2000;57(1):307-313.
Villeneuve PJ, Schaubel DE, Fenton SS, et al. Cancer incidence among canadian kidney transplant recipients. Am J Transplant. 2007;7(4):941-948.
Vajdic CM, McDonald SP, McCredie MRE, et al. Cancer incidence before and after kidney transplantation. JAMA. 2006;296(23):2823-2831.
Engels EA, Pfeiffer RM, Fraumeni JF, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306(17):1891.
Piselli P, Serraino D, Segoloni GP, et al. Risk of de novo cancers after transplantation: results from a cohort of 7217 kidney transplant recipients, Italy 1997-2009. Eur J Cancer. 2013;49(2):336-344.
Miao Y, Everly JJ, Gross TG, et al. De Novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general population. Transplantation. 2009;87(9):1347-1359.
Au EH, Chapman JR, Craig JC, et al. Overall and site-specific cancer mortality in patients on dialysis and after kidney transplant. J Am Soc Nephrol. 2019;30(3):471-480.
Benoni H, Eloranta S, Ekbom A, et al. Survival among solid organ transplant recipients diagnosed with cancer compared to nontransplanted cancer patients-a nationwide study. Int J Cancer. 2020;146(3):682-691.
Murray SL, O’Leary E, De Bhailís ÁM, et al. Cancer survival in kidney transplant recipients in Ireland. Nephrol Dial Transplant. 2020;35(10):1802-1810.
Blosser CD, Haber G, Engels EA. Changes in cancer incidence and outcomes among kidney transplant recipients in the United States over a thirty-year period. Kidney Int. 2021;99(6):1430-1438.
Chapman JR, Webster AC, Wong G. Cancer in the transplant recipient. Cold Spring Harbor Perspect Med. 2013;3(7):a015677.
Arend SM, Mallat MJ, Westendorp RJ, et al. Patient survival after renal transplantation; more than 25 years follow-up. Nephrol Dial Transplant. 1997;12(8):1672-1679.
Lim WH, Badve SV, Wong G. Long-term allograft and patient outcomes of kidney transplant recipients with and without incident cancer - a population cohort study. Oncotarget. 2017;8(44):77771-77782.
van de Wetering J, Roodnat JI, Hemke AC, et al. Patient survival after the diagnosis of cancer in renal transplant recipients: a nested case-control study. Transplantation. 2010;90(12):1542-1546.
Fröhlich FA, Halleck F, Lehner L, et al. De-novo malignancies after kidney transplantation: A long-term observational study. Dor FJ, curator. PLoS One. 2020;15(11):e0242805.
Kleinbaum DG, Klein M. Survival Analysis. 3rd ed. Springer; 2012.
Serraino D, Piselli P, Angeletti C, et al. Risk of Kaposi’s sarcoma and of other cancers in Italian renal transplant patients. Br J Cancer. 2005;92(3):572-575.
Howard RJ, Patton PR, Reed AI, et al. The changing causes of graft loss and death after kidney transplantation. Transplantation. 2002;73:1923-1928.
Wong G, Chapman JR, Craig JC. Death from cancer: a sobering truth for patients with kidney transplants. Kidney Int. 2014;85(6):1262-1264.
Schulz TF. Cancer and viral infections in immunocompromised individuals. Int J Cancer. 2009;125(8):1755-1763.
Faull RJ, Hollett P, McDonald SP. Lymphoproliferative disease after renal transplantation in Australia and New Zealand. Transplantation. 2005;80(2):193-197.
Einollahi B, Lessan-Pezeshki M, Nourbala MH, et al. Kaposi’s sarcoma following living donor kidney transplantation: review of 7,939 recipients. Int Urol Nephrol. 2009;41(3):679-685.
Woodle ES, Hanaway M, Buell J, et al. Kaposi sarcoma: an analysis of the US and international experiences from the Israel Penn international transplant tumor registry. Transplantation Proc. 2001;33(7):3660-3661.
Yanik EL, Clarke CA, Snyder JJ, et al. Variation in cancer incidence among patients with ESRD during kidney function and nonfunction intervals. J Am Soc Nephrol. 2016;27(5):1495-1504.
Buell JF, Papaconstantinou HT, Skalow B, et al. De Novo colorectal cancer: five-year survival is markedly lower in transplant recipients compared with the general population. Transplantation Proc. 2005;37(2):960-961.
Buell JF, Hanaway MJ, Trofe J, et al. De novo breast cancer in renal transplant recipients. Transplantation Proc. 2002;34(5):1778-1779.
D’Arcy ME, Coghill AE, Lynch CF, et al. Survival after cancer diagnosis among solid organ transplant recipients in the United States. Cancer. 2019;125(6):933-942.
Bratt O, Drevin L, Prütz K-G, et al. Prostate cancer in kidney transplant recipients - a nationwide register study: kidney transplants and prostate cancer. BJU Int. 2020;125(5):679-685.
Kiberd BA, Rose C, Gill JS. Cancer mortality in kidney transplantation. Am J Transplant. 2009;9(8):1868-1875.
Geissler EK, Schlitt HJ, Thomas G. mTOR, cancer and transplantation. Am J Transplant. 2008;8(11):2212-2218.
Kao C-C, Liu J-S, Chang Y-K, et al. Cancer and mTOR inhibitors in kidney transplantation recipients. Peer J. 2018;6:e5864.